ABCA1 and diabetic kidney disease: These nanoplatforms have the ability to circumvent the glomerular filtration barrier, facilitate mesangial retention, and augment cholesterol efflux, thereby presenting a potentially efficacious therapeutic option for individuals with DKD (21).PPARγ, a crucial transcription factor in macrophage cholesterol metabolism, has the potential to enhance ABCA1 transcription and cholesterol efflux by upregulating LXRα and ABCA1 sequentially (33).